Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of a Vero cell-derived inactivated Japanese encephalitis (JE) vaccine and a measles-mumps-rubella (MMR) vaccine is primarily utilized in pediatric immunization programs in regions where JE is endemic, such as Southeast Asia and the Western Pacific. The JE component, such as Biological E's JEEV or Valneva's IXIARO, uses an inactivated virus (often the SA 14-14-2 or P-3 strain) grown in Vero cells, providing a safer alternative to older mouse-brain derived vaccines. The MMR component is a standard live-attenuated trivalent vaccine. Clinical studies, notably by Biological E. Limited, have demonstrated that co-administration of these vaccines is safe and does not interfere with the immunogenicity of either component, facilitating the integration of JE vaccination into the Expanded Programme on Immunization (EPI) schedule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inactivated japanese encephalitis vaccine + measles-mumps-rubella vaccine.